[1] Astrom K E, Mancall E L, Richardson E P Jr. Progressive multifocal leukoencephalopathy:a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin’s disease[J].Brain,1958,81(1):93-111. [2] KoralnikI J. Progressive multifocalleukoencephalopathy revisited: has thedisease outgrown its name?[J]. Ann Neurol,2006,60(2): 162-173. [3] FDA.FDA Issues Public Health Advisory on Tysabri, a New Drug for MS[EB/OL]. (2005-02-28)[2016-06-15]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108413.htm. [4] Cavanagh J B, Greenbaum D, Marshall A H, et al. Cerebral demyelination associated with disorders of the reticuloendothelialsystem[J]. Lancet. 1959, 2(7012):524-529. [5] Zurheing G, Chou S M. Particles resembling papova viruses in human cerebral demyelinating disease[J]. Science,1965,148(1477): 1477-1479. [6] Padgett B L, Walker D L, ZuRhein G M, et al.Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy[J]. Lancet,1971,1(7712): 1257-1260. [7] Major E O, Amemiya K, Tomatore C S, et al. Pathogenesis andmolecular biology of progressive multifocal leukoencephalopathy, the J C virus-induced demyelinating disease of the human brain[J]. ClinMicrobiol Rev,1992,5(1): 49-73. [8] 蒋荣猛, 黄昌宏, 李兴旺. JC病毒研究进展[J]. 传染病信息, 2010,23(6): 372-375. [9] Eash S, Tavares R, Stopa E G, et al. Differential distribution of the JC virus receptor-type sialic acid in normal human tissues[J]. AmJ Pathol,2004,164(2): 419-428. [10] Khanna N, Wolbers M, Mueller N J, et a1. J C virus-specific immuneresponses in human immunodefieieney virus type l patients withprogressive multifocal leukoencephalopathy[J]. J Virol, 2009,83(9): 4404-4411. [11] Kato A, Kitamura T, Takasaka T, et al. Detection of the archetypalregulatory region of JC virus from the tonsil tissue of patients withtonsillitis and tonsillar hypertrophy[J]. J Neurovirol,2004,10(4): 244-249. [12] Hou J, Seth P, Major E O. J C virus can infect human immune and nervous system progenitor cells: implications for pathogenesis[J]. AdvExp Med Biol,2006,577: 266-273. [13] Berger J R. Progressive multifocal leukoencephalopathy[J].Handb Clin Neurol,2007,85: 169-183. [14] 刘磊, 王得新, 王佳伟. 进行性多灶性白质脑病的临床与基础 研究新进展[J]. 中国现代神经疾病杂志,2011,11(5): 504-512. [15] Angelini L, Pietrogrande M C,Delle Piane M R, et al. Progressive multifocal leukoencephalopathyin achildwith hyperimmunoglobulin E recurrent infection syndrome and review of the literature.Neuropediatrics,2001,32(5):250-255. [16] 国家食品药品监督管理总局药品评价中心. 美国修改吗 替麦考酚酯说明书警示白质脑病[EB/OL]. 药物警戒快讯. (2008-07-25)[2016-06-15]. http://www.cdr-adr.org.cn/jjkx_258/ywjjkx/2008/200812/t20081216_1700.html. [17] Khanna N, Elzi L, Mueller N J, et al. Incidence and outcome of progressive multifocal leukoencephalopathy over20 years of the Swiss HIV cohort study[J]. Clin Infect Dis,2009,48(10): 1459-1466. [18] Amend K L, Turnbull B, Foskett N, et al. Incidence of progressive multifocalleukoencephalopathy in patients without HIV[J]. Neurol, 2010, 75(15): 1326-1332. [19] Melis M, Biagi C, Smabrekke L, et al. Drug-Induced Progressive Multifocal Leukoencephalopathy: A Comprehensive Analysis of the WHO AdverseDrug Reaction Database[J]. CNS Drugs, 2015, 29(10):879-891. [20] 国家食品药品监督管理总局药品评价中心. 药物警戒快讯-美国警示芬戈莫德与严重脑部感染风险[EB/OL]. (2013-10-09) . http://www.cdr-adr.org.cn/jjkx_258/ywjjkx/2013/201310/t20131017_5652.html. [21] 国家食品药品监督管理总局药品评价中心. 药物警戒快讯-澳 大利亚发布药物性PML的相关信息[EB/OL]. 2013-03-28)[2016-06-15]. http://www.cdr-adr.org.cn/jjkx_258/ywjjkx/2013/201305/t20130508_5453.html. [22] FDA. FDA Approves Resumed Marketing of TysabriUnder aSpecial Distribution Program[EB/OL]. (2006-06-05)[2016-06-15]. http://www.fda.gov/bbs/topics/NEWS/2006/NEW01380.html. [23] 李行, 竟永华, 郭剑非. 那他珠单抗重返市场给药品风险管理的启示[J].中国药物警戒,2007,13(1): 14-16, 26. |